Classification
- Anatomical main groupLAntineoplastic and immunomodulating agents
- Therapeutic subgroupL01Antineoplastic agents
- Pharmacological subgroupL01F
- Chemical subgroupL01FXOther monoclonal antibodies and antibody drug conjugates
- Chemical substanceL01FX18Amivantamab
Where it is registered
Each register and historical list with its number of registrations and a few of them.
At a glance
- ATC code
- L01FX18
- Registers
- 10
- Registrations
- 25
- With their own page
- 25
- Companies
- 7
All medicines with Amivantamab
Human medicines from every register that match Amivantamab by substance or by name, a page at a time, so the count can differ from the registrations above. Strengths and packs are on each medicine’s page.
25 search results
| Medicine | Register | Strength | Form | Status | Holder |
|---|---|---|---|---|---|
| Rybrevant | United States | 350MG/7ML | injectable | Marketed | Janssen Biotech |
| Rybrevant FasproCombination | United States | 10ML, 14ML | injection | Marketed | Janssen Biotech |
| Rybrevant FasproCombination | United States | 1,600MG/20,000 UNITS PER 10ML, 2,240MG/28,000 UNITS PER 14ML, 2,400MG/30,000 UNITS PER 15ML … | vial | Marketed | Janssen Biotech |
| Rybrevant | European Union | Authorised | Janssen-Cilag International N.V. | ||
| Rybrevant 1600 MG Solucion Inyectable | Spain | 1600 mg | solución inyectable | Marketed | Janssen-Cilag International N.V |
| Rybrevant 2240 MG Solucion Inyectable | Spain | 2240 mg | solución inyectable | Marketed | Janssen-Cilag International N.V |
| Rybrevant 2400 MG Solucion Inyectable | Spain | 2400 mg | solución inyectable | Marketed | Janssen-Cilag International N.V |
| Rybrevant 3520 MG Solucion Inyectable | Spain | 3520 mg | solución inyectable | Marketed | Janssen-Cilag International N.V |
| Rybrevant 350 MG Concentrado Para Solucion Para Perfusion | Spain | 350 mg | concentrado para solución para perfusión | Marketed | Janssen-Cilag International N.V |
| Rybrevant | Canada | 350 MG / 7 ML | Solution | Marketed | Janssen INC |
| Rybrevant 1600 mg, oplossing voor injectie | Netherlands | Oplossing voor injectie | Authorised | Janssen-Cilag International NV | |
| Rybrevant 2240 mg, oplossing voor injectie | Netherlands | Oplossing voor injectie | Authorised | Janssen-Cilag International NV | |
| Rybrevant 2.400 mg oplossing voor injectie | Netherlands | Oplossing voor injectie | Authorised | Janssen-Cilag International NV | |
| Rybrevant 3.520 mg oplossing voor injectie | Netherlands | Oplossing voor injectie | Authorised | Janssen-Cilag International NV | |
| Rybrevant SC | Canada | 2240 MG / 14 ML | Solution | Marketed | Janssen INC |
| Rybrevant SC | Canada | 3520 MG / 22 ML | Solution | Marketed | Janssen INC |
| Rybrevant SC | Canada | 1600 MG / 10 ML | Solution | Marketed | Janssen INC |
| Rybrevant SC | Canada | 2400 MG / 15 ML | Solution | Marketed | Janssen INC |
| Rybrevant 350 mg, concentraat voor oplossing voor infusie | Netherlands | Concentraat voor oplossing voor infusie | Authorised | Janssen-Cilag International NV | |
| Rybrevant | Brazil | Authorised | Janssen-Cilag Farmacêutica Ltda | ||
| Rybrevant® | Serbia | 350mg/7mL | koncentrat za rastvor za infuziju | Authorised | PredstavniŠTvo Janssen-Cilag KFT Beograd |
| Rybrevant | Croatia | Marketed | |||
| Rybrevant Solution for Injection 160 mg/mL | Taiwan | 注射液劑 | Authorised | 嬌生股份有限公司 | |
| Rybrevant Concentrate for Solution for Infusion 50mg/ml | Taiwan | 注射劑 | Authorised | 嬌生股份有限公司 | |
| Rybrevant Concentrate for Solution for Infusion 350MG/7ML | Singapore | 350mg/7ml | infusion, solution concentrate | Authorised | Johnson & Johnson International (Singapore) Pte LTD |